Related Experiment Video

Updated: May 8, 2026

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

MEK inhibition in the treatment of advanced melanoma

April K S Salama1, Kevin B Kim

  • 1Division of Medical Oncology, Duke University Medical Center, DUMC 3476, Durham, NC, 27710, USA, april.salama@duke.edu.

Current Oncology Reports
|August 27, 2013
PubMed

Insights

Targeting the MEK-ERK pathway with MEK inhibitors shows promise for melanoma treatment. Trametinib is approved for BRAF-mutant melanoma, and other MEK inhibitors may benefit patients with NRAS or other mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • The RAS-RAF-MEK-ERK pathway is crucial in melanoma development.
  • Genetic mutations, particularly BRAF and NRAS, drive melanoma.
  • MEK is a key protein in this signaling pathway, making it a therapeutic target.

Purpose of the Study:

  • To review preclinical and clinical data on MEK inhibitors in advanced melanoma.
  • To discuss the role of MEK inhibition in melanoma treatment strategies.

Main Methods:

  • Review of existing preclinical studies on MEK inhibitors.
  • Analysis of clinical trial data for MEK inhibitors in melanoma patients.
  • Discussion of therapeutic implications based on genetic mutations.

Main Results:

  • Trametinib, a MEK inhibitor, improves survival in V600 BRAF-mutant metastatic melanoma.
  • Trametinib has FDA approval for this specific patient group.
  • MEK inhibitors show potential for treating advanced melanoma with NRAS and GNAQ/GNA11 mutations.

Conclusions:

  • MEK inhibitors represent a significant advancement in targeted melanoma therapy.
  • Further investigation into MEK inhibitors for various melanoma mutations is warranted.
  • Targeting the MEK-ERK pathway offers a viable therapeutic strategy for advanced melanoma.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy09:17

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...